• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond
Curr Atheroscler Rep. 2022 Jul 29. doi: 10.1007/s11883-022-01057-z. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Since the discovery of PCSK9 in 2003, this proprotein convertase was shown to target specific receptors for degradation in endosomes/lysosomes, including LDLR and other family members and hence to enhance the levels of circulating LDL-cholesterol (LDLc). Accordingly, inhibitors of PCSK9, including monoclonal antibodies blocking its circulating activity and siRNA silencers of its hepatic expression, are now used in clinics worldwide to treat hypercholesterolemia patients effectively and safely in combination ...
Source: Atherosclerosis - July 29, 2022 Category: Cardiology Authors: Nabil G Seidah Damien Gar çon Source Type: research